Suppr超能文献

系统评价与荟萃分析:根据世界内镜组织方法得出的结肠镜检查后三年结直肠癌发生率

Systematic Review and Meta-analysis: The Three-year Post-colonoscopy Colorectal Cancer Rate as per the World Endoscopy Organization Methodology.

作者信息

Kader Rawen, Hadjinicolaou Andreas V, Burr Nicholas E, Bassett Paul, Ahmad Omer F, Pedersen Lasse, Chand Manish, Valori Roland, Stoyanov Danail, Lovat Laurence B

机构信息

Wellcome/EPSRC Centre for Interventional and Surgical Sciences (WEISS), University College London (UCL), London, United Kingdom.

Department of Gastroenterology, Cambridge University Hospitals, Cambridge, United Kingdom; Early Cancer Institute, University of Cambridge, Cambridge, United Kingdom.

出版信息

Clin Gastroenterol Hepatol. 2025 Mar;23(4):519-530. doi: 10.1016/j.cgh.2024.07.039. Epub 2024 Aug 27.

Abstract

BACKGROUND & AIMS: In 2018, the World Endoscopy Organization (WEO) introduced standardized methods for calculating post-colonoscopy colorectal cancer-3yr rates (PCCRC-3yr). This systematic review aimed to calculate the global PCCRC-3yr according to the WEO methodology, its change over time, and to measure the association between risk factors and PCCRC occurrences.

METHODS

We searched 5 databases from inception until January 2024 for PCCRC-3yr studies that strictly adhered to the WEO methodology. The overall pooled PCCRC-3yr was calculated. For risk factors and time-trend analyses, the pooled PCCRC-3yr and odds ratios (ORs) of subgroups were compared.

RESULTS

Several studies failed to adhere to the WEO methodology. Eight studies from 4 Western European and 2 Northern American countries were included, totalling 220,106 detected-colorectal cancers (CRCs) and 18,148 PCCRCs between 2002 and 2017. The pooled Western World PCCRC-3yr was 7.5% (95% confidence interval [CI], 6.4%-8.7%). The PCCRC-3yr significantly (P < .05) decreased from 7.9% (95% CI, 6.6%-9.4%) in 2006 to 6.7% (95% CI, 6.1%-7.3%) in 2012 (OR, 0.79; 95% CI, 0.72-0.87). There were significantly higher rates for people with inflammatory bowel disease (PCCRC-3yr, 29.3%; OR, 6.17; 95% CI, 4.73-8.06), prior CRC (PCCRC-3yr, 29.8%; OR, 3.03; 95% CI, 1.34-4.72), proximal CRC (PCCRC-3yr, 8.6%; OR, 1.51; 95% CI, 1.41-1.61), diverticular disease (PCCRC 3-yr, 11.6%; OR, 1.74; 95% CI, 1.37-2.10), and female sex (PCCRC-3yr, 7.9%; OR, 1.15; 95% CI, 1.11-1.20).

CONCLUSION

According to the WEO methodology, the Western World PCCRC-3yr was 7.5%. Reassuringly, this has decreased over time, but further work is required to identify the reasons for PCCRCs, especially in higher-risk groups. We devised a WEO methodology checklist to increase its adoption and standardise the categorization of patients in future PCCRC-3yr studies.

摘要

背景与目的

2018年,世界内镜组织(WEO)推出了计算结肠镜检查后结直肠癌3年发生率(PCCRC - 3yr)的标准化方法。本系统评价旨在根据WEO方法计算全球PCCRC - 3yr,分析其随时间的变化,并衡量风险因素与PCCRC发生之间的关联。

方法

我们检索了5个数据库,从数据库建立至2024年1月,查找严格遵循WEO方法的PCCRC - 3yr研究。计算总体合并的PCCRC - 3yr。对于风险因素和时间趋势分析,比较亚组的合并PCCRC - 3yr和比值比(OR)。

结果

多项研究未遵循WEO方法。纳入了来自4个西欧国家和2个北美国家的8项研究,2002年至2017年间共有220,106例检测到的结直肠癌(CRC)和18,148例PCCRC。西方世界合并的PCCRC - 3yr为7.5%(95%置信区间[CI],6.4% - 8.7%)。PCCRC - 3yr从2006年的7.9%(95% CI,6.6% - 9.4%)显著(P <.05)降至2012年的6.7%(95% CI,6.1% - 7.3%)(OR,0.79;95% CI,0.72 - 0.87)。炎症性肠病患者的发生率显著更高(PCCRC - 3yr,29.3%;OR,6.17;95% CI,4.73 - 8.06),既往有CRC者(PCCRC - 3yr,29.8%;OR,3.03;95% CI,1.34 - 4.72),近端CRC患者(PCCRC - 3yr,8.6%;OR,1.51;95% CI,1.41 - 1.61),憩室病患者(PCCRC 3年发生率,11.6%;OR,1.74;95% CI,1.37 - 2.10),以及女性(PCCRC - 3yr,7.9%;OR,1.15;95% CI,1.11 - 1.20)。

结论

根据WEO方法,西方世界的PCCRC - 3yr为7.5%。令人欣慰的是,这一发生率随时间有所下降,但仍需要进一步研究以确定PCCRC发生的原因,尤其是在高危人群中。我们设计了一份WEO方法检查表,以提高其采用率,并在未来的PCCRC - 3yr研究中规范患者分类。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验